Skip to main content

Advertisement

Table 3 Cox proportional hazards analysis of time to first AIDS event following initiation of HAART by period of HAART initiation

From: Trends in reported AIDS defining illnesses (ADIs) among participants in a universal antiretroviral therapy program: an observational study

Variable Unadjusted Hazard Ratio (95% CI) p-value Adjusted Hazard Ratio (95% CI) p-value Adjusted Hazard Ratio (95% CI) p-value
    w/adherence   w/o adherence  
Age (per decade) 1.16 (1.01-1.32) 0.031 1.18 (1.03-1.35) 0.020   
Gender   0.133     
Female 1.00      
Male 1.33 (0.92-1.94)      
Baseline AIDS defining illness 1.93 (1.42-2.63) < 0.001     
CD4 (per 100 cells) 0.64 (0.57-0.72) < 0.001     
Baseline CD4       
< 50 4.76 (3.38-6.70) < 0.001 3.56 (2.48-5.11) < 0.001 3.48 (2.43-4.99) < 0.001
50-199 1.93 (1.37-2.70) < 0.001 1.61 (1.14-2.28)   1.60 (1.13-2.26) 0.008
200+ 1.00   1.00 0.007 1.00  
Baseline Viral Load (log10) 3.32 (1.99-5.54) < 0.001 2.07 (1.50-2.85) < 0.001 2.03 (1.47-2.79) < 0.001
Baseline Viral Load   < 0.001     
< 100,000 1.00      
> 100,000 2.67 (1.96-3.64)      
Third drug of baseline therapy   0.003   0.073   0.096
PI 1.00   1.00   1.00  
NNRTI 0.64 (0.47-0.86)   0.75 (0.55-1.03)   0.77 (0.56-1.05)  
Hepatitis C   0.595     
Negative 1.00 0.560     
Positive 1.08 (0.81-1.43)      
unknown 1.15 (0.73-1.81)      
History of Injection drug use 1.12 (0.85-1.46) 0.424     
Year therapy started (per year increase) 1.03 (0.99-1.07) 0.189     
ERA therapy started       
96-98 1.00   1.00   1.00  
99-01 1.25 (0.83-1.87) 0.286 1.25 (0.82-1.91) 0.293 1.24 (0.81-1.88) 0.320
02-04 1.77 (1.20-2.60) 0.004 1.59 (1.06-2.39) 0.025 1.55 (1.04-2.32) 0.032
05-07 1.26 (0.85-1.86) 0.251 1.36 (0.90-2.04) 0.141 1.26 (0.85-1.88) 0.255
One-year Adherence (per 10% increase) 0.89 (0.86-0.93) < 0.001     
One-year Adherence   < 0.001   < 0.001   
< 95% 1.00   1.00    
≥ 95% 0.50 (0.38-0.65)   0.42 (0.32-0.56)